Otros idiomas NovoCure Limited

Acciones

NVCR

JE00BYSS4X48

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 17/05/2024			Varia. Cinco días.	Varia. 1 de enero.
21,99 ^USD	-0,81 %		+33,52 %	+47,29 %

02/05	Las acciones de NovoCure se mantienen estables tras informar de una menor pérdida en el 1T y mayores ingresos	MT
02/05	BioPharma Credit firma un acuerdo de préstamo de 400 millones de dólares con Novocure Luxembourg	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

NovoCure Shares Steady After Reporting Narrower Q1 Loss, Higher Revenue	02/05
BioPharma Credit Enters $400 Million Loan Agreement with Novocure Luxembourg	02/05
BioPharma Credit agrees USD400 million loan for oncology firm Novacure	02/05
NovoCure: Q1 Earnings Snapshot	02/05
Earnings Flash (NVCR) NOVOCURE Reports Q1 Revenue $138.5M, vs. Street Est of $131.5M	02/05
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon	02/05
Novocure Reports First Quarter 2024 Financial Results	02/05
NovoCure Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05
Novocure Enters into New Five-Year Up to $400 Million Committed Senior Secured Credit Facility with Funds Managed by Pharmakon Advisors, LP	02/05
NovoCure Limited announced that it expects to receive $400 million in funding	02/05
Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024	24/04
NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer	24/04
NovoCure : Corporate responsibility report	22/04
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research Annual Meeting 2024	08/04
NovoCure Says New Data Show TTFields' Potential Therapeutic Effects in Pancreatic Cancer	05/04
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024	05/04
Novocure to Report First Quarter 2024 Financial Results	01/04
Klinische Phase-3-Studie METIS erreicht primären Endpunkt und zeigt eine statistisch signifikante Verlängerung der Zeit bis zur intrakraniellen Progression bei Patient:innen mit Hirnmetastasen von nicht-kleinzelligem Lungenkrebs	28/03
L’essai clinique de phase 3 METIS a atteint son critère principal, démontrant un allongement statistiquement significatif du délai médian jusqu’à la progression intracrânienne chez les patients porteurs de métastases cérébrales consécutives...	28/03
Novocure - METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer	28/03

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas NovoCure Limited

Acciones

NVCR

JE00BYSS4X48

Otros idiomas

Filtros